Published: March 2014 Read Executive Summary Read Full-Text Document This white paper offers guidance in the following three areas: 1) general safety and quality, including procedures; roles and qualification for the members of the brachytherapy team; source radionuclides, and types of reported medical events; 2) clinical applications for HDR brachytherapy by disease site, including intraluminal and intraoperative brachytherapy; and 3) key measures to avoid catastrophic failures.
Endorsed by:
Resources: Value of MRI without/with applicator in place for target definition in cervix cancer brachytherapy (CME) Advancements in Clinical Brachytherapy (CME) Podcast with document chair ASTRO’s Brachytherapy Model Policy
We have recently updated our privacy policy and terms of use. By using this site, you agree to ASTRO’s Privacy Policy and Terms of Use. We use cookies to provide, secure and improve our services to you. To learn more, click here.